Replies to post #9572 on Momenta Pharmaceuticals, Inc. (MNTA)

[iwfal]

<<The FDA can approve NVS/MNTA’s Copaxone ANDA irrespective of the patent litigation.>>
- and then agreeing 100% with him:
What you say makes sense, else how would generics be launched at-risk.

I think you must admit that this was BS.

I suggest you need a reminder of the sequence of events and your claims:

1) the post/thread you linked to was a June 23rd post where you claimed at that the FDA could no longer give final approval to mcopaxone. This was untrue at that instant since the court had entered no such order.

2) later, July 25th or so, the court did enter such an order and at that instant you became correct where you had not been so before on this topic.

A more useful discussion on this topic would have been about the percent of DC patent rulings that result in such orders to the FDA and now a more interesting discussion is the rate at which appeals void these kinds of orders - although it isn't hugely more interesting given Momenta's statement that they will not launch at risk.

FWIW I find your pushback somewhat useful on this board although given the tendency of such discussions with you to devolve into counting coup it isn't anywhere near as useful it could be.